SCYX (SCYNEXIS) LT-Debt-to-Total-Asset : 0.02 (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is SCYNEXIS LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. SCYNEXIS's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.02.

SCYNEXIS's long-term debt to total assets ratio declined from Dec. 2023 (0.12) to Dec. 2024 (0.02). It may suggest that SCYNEXIS is progressively becoming less dependent on debt to grow their business.

SCYNEXIS LT-Debt-to-Total-Asset Historical Data

The historical data trend for SCYNEXIS's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS LT-Debt-to-Total-Asset Chart

SCYNEXIS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.19

0.36

0.55

0.12

0.02

SCYNEXIS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.12	0.02	0.02	0.02	0.02

SCYNEXIS LT-Debt-to-Total-Asset Calculation

SCYNEXIS's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	2.175	/	90.643
	=	0.02

SCYNEXIS's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	2.175	/	90.643
	=	0.02

SCYNEXIS (NAS:SCYX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

SCYNEXIS LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

SCYNEXIS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (NAS:SCYX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

0L49:UK 135A:Germany

Address

1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548

Website

https://www.scynexis.com

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Executives

Gonzalez David Angulo	officer: Chief Medical Officer	C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
David C Hastings	director	C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Brian Philippe Tinmouth	director	1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Guy Macdonald	director	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Armando Anido	director	80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Ann Hanham	director	ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Ivor Macleod	officer: Chief Financial Officer	3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
Scott Sukenick	officer: General Counsel	101 HUDSON STREET, SUITE 3610, JERSEY CITY NJ 07302
Marco Taglietti	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Lawrence R Hoffman	officer: Interim CFO	C/O COVALENT GROUP, INC., 1275 DRUMMERS LANE, SUITE 100, WAYNE PA 19087
Christine Coyne	officer: Chief Commercial Officer	1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric Francois	officer: Chief Financial Officer	C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713